Hair Thinning in Women: What Could Be Causing It

Why Women Lose Hair Differently Than Men

Women's hair loss is biologically distinct. Full stop.

The popular image of hair thinning, a receding hairline with a bald crown, describes the male androgenetic pattern. In women, androgenetic alopecia usually presents as diffuse thinning at the crown with a widened central part, a preserved frontal hairline, and far more variation in severity across the menstrual cycle and hormonal life stages. Female pattern hair loss (FPHL) affects an estimated 40% of women by age 50 and can begin as early as the late 20s.

What complicates diagnosis is that several causes frequently overlap. A woman in perimenopause may have falling estrogen, borderline low ferritin, and subclinical hypothyroidism simultaneously, and all three are contributing to her shedding. Treating only one and ignoring the others produces disappointing results.

The biology behind why hormones matter so much

Hair follicles are estrogen-sensitive. Estrogen prolongs the growth (anagen) phase and appears to partially oppose the effect of dihydrotestosterone (DHT) on susceptible follicles. When estrogen drops, as it does sharply after delivery or gradually through perimenopause, the relative androgenic influence at the follicle rises. A 2020 review in the Journal of Investigative Dermatology confirmed that estrogen receptors are present throughout the hair follicle and that declining estrogen accelerates the shift from anagen to telogen (the resting/shedding phase).

This is why timing your hair thinning to your hormonal life stage is clinically useful. It narrows the differential before any lab is ordered.

Cause 1: Female Pattern Hair Loss (Androgenetic Alopecia)

Female pattern hair loss is the most common chronic cause of thinning in women, and it is still under-diagnosed because clinicians often expect the male presentation. The Ludwig scale, which grades thinning at the crown from Grade I (mild widened part) to Grade III (near-complete crown loss), is the standard clinical tool.

Who it affects most

FPHL is androgen-sensitive but not always androgen-driven in the same way as in men. Roughly 50% of women with FPHL have normal serum androgens, which means the follicles themselves are more sensitive to normal androgen levels rather than levels being abnormally high. Women with PCOS, who do have elevated androgens, tend to develop FPHL earlier and more severely, often with a more diffuse pattern extending to the temporal areas.

How menopause changes it

The estrogen withdrawal of perimenopause removes the partial protection estrogen provided at the follicle level. The Menopause Society (formerly NAMS) notes that postmenopausal women experience accelerated FPHL because falling estrogen allows DHT to act more freely on susceptible follicles. This is one reason some postmenopausal women ask whether hormone therapy (HT) helps their hair. The data are limited, but non-androgenic progestogens such as progesterone or dydrogesterone are preferred in HT formulations for women concerned about hair, since androgenic progestins (norethindrone, levonorgestrel) may worsen FPHL.

Cause 2: Telogen Effluvium, The Shedding Surge

Telogen effluvium (TE) is diffuse hair shedding triggered when a physiological stressor pushes a large proportion of follicles into the resting (telogen) phase simultaneously. The shedding appears 6 to 16 weeks after the trigger, so women often cannot connect the cause to the symptom.

Common triggers in women include:

• Childbirth (postpartum TE is the most common form)
• Rapid caloric restriction or crash dieting
• Major surgery or significant illness
• Severe psychological stress or trauma
• Starting or stopping oral contraceptives
• Sudden discontinuation of hormone therapy

Postpartum hair loss: what to expect

During pregnancy, rising estrogen holds more follicles in the anagen (growth) phase. After delivery, estrogen falls sharply and those follicles enter telogen en masse. Postpartum TE typically peaks between months 3 and 6 and resolves on its own by 9 to 12 months in most women. No treatment is required, but addressing any concurrent iron deficiency (common postpartum) speeds recovery. A ferritin below 30 ng/mL will prolong shedding even after the hormonal trigger resolves.

Chronic telogen effluvium

When shedding persists beyond 6 months without full recovery, it is classified as chronic TE. This form is more common in women aged 30 to 60 and is frequently associated with iron deficiency, thyroid disease, or an underlying inflammatory condition. A pull test showing >10% telogen hairs confirms active shedding; trichoscopy can distinguish TE from FPHL when clinical findings are ambiguous.

Cause 3: Thyroid Disease

Thyroid dysfunction is one of the most frequently missed contributors to hair thinning in women, partly because the hair loss is diffuse and partly because thyroid symptoms build slowly. Both hypothyroidism and hyperthyroidism can cause hair loss by disrupting the hair cycle, though the mechanism differs.

Women are 5 to 8 times more likely than men to develop thyroid disease, which is one reason thyroid function is a first-line test in any woman presenting with diffuse hair thinning. Hashimoto's thyroiditis, the autoimmune form of hypothyroidism, is particularly common in women of reproductive age and in the perimenopause transition.

What TSH level is enough?

A TSH in the high-normal range (above 2.5 mIU/L in some functional medicine frameworks, though the standard lab cutoff is 4.5 to 5.0 mIU/L) is debated as a hair loss threshold. The honest answer is that the evidence for treating subclinical hypothyroidism specifically for hair loss is thin. What is established: overt hypothyroidism (TSH >5.0 with low free T4) does cause diffuse hair thinning, and levothyroxine treatment reverses it within 3 to 6 months of achieving euthyroid status.

Postpartum thyroiditis

Postpartum thyroiditis (PPT) affects 5 to 10% of women in the first year after delivery and is a distinct autoimmune flare separate from pre-existing Hashimoto's. It typically follows a hyperthyroid phase (weeks 1 to 4 postpartum) followed by a hypothyroid phase (months 4 to 8), and hair thinning may appear during either phase. Most cases resolve spontaneously, but 20 to 30% of women develop permanent hypothyroidism within 5 years.

Cause 4: Iron Deficiency

Iron deficiency is the single most commonly overlooked reversible cause of hair thinning in premenopausal women. Heavy menstrual periods, inadequate dietary iron, pregnancy, and breastfeeding all deplete iron stores. The hair follicle is a metabolically active structure that requires iron for DNA synthesis during the rapid proliferation of anagen.

The critical lab value is serum ferritin, not hemoglobin. A woman can have a normal hemoglobin and still have ferritin low enough to drive hair loss. A 2013 review in the Journal of the American Academy of Dermatology identified ferritin below 30 ng/mL as associated with telogen effluvium, though some dermatologists use a threshold of 40 to 70 ng/mL for hair-specific optimization.

Correcting iron deficiency with oral ferrous sulfate 325 mg (65 mg elemental iron) daily, or ferrous bisglycinate for better tolerability, typically takes 3 to 6 months to replete stores. Women with heavy menstrual bleeding lose, on average, 30 to 40 mg of iron per period, which can outpace dietary intake even with a varied diet.

Cause 5: PCOS and Elevated Androgens

Polycystic ovary syndrome (PCOS) affects 8 to 13% of women of reproductive age and is among the most common hormonal causes of hair thinning in the 20s and 30s. Elevated DHEA-S, free testosterone, or androstenedione drives follicle miniaturization in genetically susceptible women, producing a diffuse thinning pattern that often coexists with hirsutism (increased facial and body hair) and hormonal acne.

How to tell PCOS hair loss from FPHL

The distinction matters for treatment. Both produce crown thinning, but PCOS-related loss tends to appear earlier (teens to mid-30s), is more likely to involve temporal thinning, and is accompanied by other signs of hyperandrogenism. Lab findings of elevated free testosterone or DHEA-S with menstrual irregularity clinch the diagnosis. The 2023 international evidence-based PCOS guideline recommends combined oral contraceptives as the first-line pharmacological treatment for hyperandrogenism symptoms including hair loss in women not trying to conceive.

Spironolactone for androgen-driven hair loss

Spironolactone 50 to 200 mg/day is the most commonly prescribed anti-androgen for FPHL and PCOS-related hair loss in the United States. A 2020 retrospective study of 1,000 women in JAMA Dermatology found that 74.4% of women reported improvement or stabilization with spironolactone for female pattern hair loss. It requires reliable contraception (see pregnancy safety section below) because it is a potent teratogen in male fetuses.

Cause 6: Alopecia Areata and Inflammatory Scalp Conditions

Alopecia areata (AA) is an autoimmune condition where the immune system attacks hair follicles, producing patchy, non-scarring hair loss. It affects women and men equally but may be triggered or worsened by hormonal events in women. AA flares during postpartum periods and at perimenopause have been reported, likely related to immune shifts that accompany hormonal transitions.

Other inflammatory conditions that thin hair include:

• Lupus (discoid or systemic), which can cause scarring alopecia
• Lichen planopilaris, a scarring alopecia that peaks in perimenopause
• Seborrheic dermatitis, which does not scar but drives chronic diffuse shedding when untreated

Scarring alopecias are medical emergencies in the sense that follicle destruction is permanent once fibrosis sets in. Any woman with scalp pain, burning, or patchy hair loss that leaves smooth, shiny skin behind should be seen urgently by a dermatologist. A scalp biopsy is the definitive diagnostic test.

How Hair Thinning Is Diagnosed

A structured workup beats the "try a supplement and see" approach. Here is what a thorough evaluation typically includes.

First-line blood panel

| Test | What it rules in or out | |---|---| | TSH, free T4 | Hypothyroidism, hyperthyroidism | | Ferritin, CBC | Iron deficiency, anemia | | Free and total testosterone | PCOS, hyperandrogenism | | DHEA-S | Adrenal androgen excess | | Prolactin | Hyperprolactinemia | | 25-OH Vitamin D | Deficiency linked to AA and TE | | ANA | Lupus-related scarring alopecia | | HbA1c or fasting glucose | Metabolic dysfunction |

Trichoscopy and scalp biopsy

A trained dermatologist using a dermatoscope can assess follicular density, miniaturized follicles, and scalp inflammation without biopsy in most cases. Trichoscopy has a sensitivity of approximately 70 to 80% for distinguishing FPHL from TE when performed by an experienced clinician. Scalp biopsy remains the gold standard for scarring alopecias.

The WomanRx Hair Thinning Diagnostic Framework by Life Stage

| Life stage | Most likely cause | Second-line workup | |---|---|---| | Reproductive years (18-40) | Iron deficiency, PCOS, TE | Androgen panel, ferritin, hormonal contraceptive history | | Pregnancy and postpartum | Postpartum TE, PPT, iron deficiency | Ferritin, TSH at 6-8 weeks postpartum | | Perimenopause (40-52) | FPHL acceleration, TE from hormonal shift, thyroid | Estradiol, FSH, TSH, ferritin | | Post-menopause | FPHL, lichen planopilaris, systemic disease | Scalp exam, ANA, biopsy if scarring |

Treatments That Work: Evidence by Cause

Minoxidil (topical and oral)

Minoxidil 2% to 5% topical solution or foam is the only FDA-approved topical treatment for FPHL. A 2014 Cochrane review confirmed that minoxidil 2% improves hair density versus placebo in women with FPHL, with 5% showing marginally better efficacy but more scalp irritation. Low-dose oral minoxidil (0.25 to 1 mg/day) is increasingly used off-label and may be better tolerated for women who find topical application difficult.

Spironolactone

As noted above, spironolactone 100 to 200 mg/day reduces androgen activity at the follicle. Response takes 6 to 12 months and requires ongoing use to maintain results. Blood pressure and potassium monitoring is recommended, particularly in the first 3 months.

Hormone therapy for menopausal women

Estrogen-containing HT may slow FPHL progression in postmenopausal women, though this is not an FDA-approved indication and the data are largely observational. A 2021 paper in Menopause journal noted that women using systemic estrogen reported less perceived hair thinning than non-users, but controlled trial data are lacking. If HT is chosen for other menopausal symptoms, a progestin with low androgenicity (oral progesterone, dydrogesterone) is preferable for hair-concerned women.

Addressing root causes

Correcting thyroid disease, repleting iron to a ferritin above 40 ng/mL, and managing PCOS with metformin or combined oral contraceptives addresses the upstream driver rather than the follicle directly. These interventions produce slower but more durable results than topical therapies alone.

Pregnancy, Postpartum, and Contraception Safety

This section covers every treatment mentioned above for women who are pregnant, trying to conceive, or breastfeeding.

Minoxidil: FDA Pregnancy Category C. Animal studies show fetal harm at high oral doses; no controlled human pregnancy data exist for topical use. The FDA advises stopping minoxidil before conception and not using it during breastfeeding because excretion in breast milk has been reported in at least one case.

Spironolactone: Contraindicated in pregnancy. Spironolactone is an anti-androgen and animal studies demonstrate feminization of male fetuses. ACOG recommends that any woman of reproductive age taking spironolactone use highly effective contraception, such as an intrauterine device, implant, or combined oral contraceptive. It is not recommended during breastfeeding due to unknown transfer into milk and potential hormonal effects on the infant.

Combined oral contraceptives (for PCOS-related hair loss): Contraindicated in pregnancy. They are the most effective contraception while treating PCOS-related hair loss. Note that some progestin-only pills have androgenic activity (norethindrone) and may worsen hair thinning; prefer pills with drospirenone or norgestimate if hair is a concern.

Iron supplementation: Safe in pregnancy and actively recommended. The recommended daily iron intake rises to 27 mg/day during pregnancy, and supplementation is first-line for deficiency.

Levothyroxine for hypothyroidism: Safe in pregnancy and essential. Dose requirements increase by approximately 25 to 30% in the first trimester. TSH should be checked every 4 weeks in the first half of pregnancy and adjusted accordingly per American Thyroid Association 2017 guidelines.

Who This Is Right For, and Who Needs a Different Path

Women who are good candidates for self-directed care

• Postpartum shedding with confirmed normal thyroid and ferritin above 30 ng/mL: watchful waiting is appropriate
• Diffuse thinning after a clear stressor (crash diet, illness, surgery) with no other abnormal labs: address the trigger and monitor

Women who need specialist input promptly

• Any patchy hair loss with scalp symptoms (pain, burning, itch): dermatology urgently
• Hair loss with signs of hyperandrogenism (irregular periods, acne, hirsutism): endocrinology or reproductive endocrinology
• Postmenopausal women with rapidly progressive thinning: scalp biopsy to rule out scarring alopecia before follicles are permanently lost
• Hair loss during pregnancy beyond expected postpartum timing: rule out nutritional deficiency and autoimmune disease; do not start minoxidil or spironolactone

The evidence gap worth naming

Women were excluded from or under-represented in the majority of early androgenetic alopecia trials, which is why many dosing recommendations for minoxidil and finasteride (not approved for women in most countries due to teratogenicity) are extrapolated from male data. The growing body of female-specific research is promising but still thinner than the clinical need warrants. When a treatment recommendation feels uncertain, that uncertainty is real and reflecting it honestly is part of good care.

When to Worry About Hair Thinning

Hair loss becomes an urgent concern in these situations:

• You are losing more than 100 to 150 hairs per day consistently over 8 weeks
• The scalp is visible through the hair at the crown or part without recent hormonal change
• You notice bald patches developing over days rather than weeks
• Hair loss is accompanied by fatigue, weight change, palpitations, or skin changes that suggest systemic disease
• A postpartum woman's shedding has not slowed at all by month 9 to 12

Any of these findings means a workup now, not in another few months of waiting and watching.